Steroid shots linked to fatal meningitis, CDC says
NASHVILLE — An outbreak of a rare and deadly form of meningitis has sickened 26 people in five states who received steroid injections, said health officials on Wednesday. Four people have died.
Eighteen of the cases are in Tennessee, where a Nashville clinic received the largest shipment of the steroid suspected in the outbreak. The drug — commonly prescribed for back pain —was manufactured by New England Compounding Center in Massachusetts, which has issued a recall.
Three cases have been reported in Virginia, two in Maryland, two in Florida and one in North Carolina. Two of the deaths were in Tennessee; Virginia and Maryland had one each, said the Centers for Disease Control and Prevention.
More cases are expected to surface, said Tennessee Department of Health.
Investigators have been looking into at least three products used for the back injections that could have been tainted by the fungus that appears to be behind the illnesses.
None of the products have been ruled out, they said.
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments â either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.